These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23002282)

  • 1. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.
    Kaye SB; Poole CJ; Dańska-Bidzińska A; Gianni L; Del Conte G; Gorbunova V; Novikova E; Strauss A; Moczko M; McNally VA; Ross G; Vergote I
    Ann Oncol; 2013 Jan; 24(1):145-52. PubMed ID: 23002282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
    Kurzeder C; Bover I; Marmé F; Rau J; Pautier P; Colombo N; Lorusso D; Ottevanger P; Bjurberg M; Marth C; Barretina-Ginesta P; Vergote I; Floquet A; Del Campo JM; Mahner S; Bastière-Truchot L; Martin N; Oestergaard MZ; Kiermaier A; Schade-Brittinger C; Polleis S; du Bois A; Gonzalez-Martin A
    J Clin Oncol; 2016 Jul; 34(21):2516-25. PubMed ID: 27269942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
    Lorusso D; Hilpert F; González Martin A; Rau J; Ottevanger P; Greimel E; Lück HJ; Selle F; Colombo N; Kroep JR; Mirza MR; Berger R; Pardo B; Grischke EM; Berton-Rigaud D; Martinez-Garcia J; Vergote I; Redondo A; Cardona A; Bastière-Truchot L; du Bois A; Kurzeder C;
    Int J Gynecol Cancer; 2019 Sep; 29(7):1141-1147. PubMed ID: 31420414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
    Makhija S; Amler LC; Glenn D; Ueland FR; Gold MA; Dizon DS; Paton V; Lin CY; Januario T; Ng K; Strauss A; Kelsey S; Sliwkowski MX; Matulonis U
    J Clin Oncol; 2010 Mar; 28(7):1215-23. PubMed ID: 19901115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
    Vergote I; Armstrong D; Scambia G; Teneriello M; Sehouli J; Schweizer C; Weil SC; Bamias A; Fujiwara K; Ochiai K; Poole C; Gorbunova V; Wang W; O'Shannessy D; Herzog TJ
    J Clin Oncol; 2016 Jul; 34(19):2271-8. PubMed ID: 27001568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
    Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
    Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
    Secord AA; Blessing JA; Armstrong DK; Rodgers WH; Miner Z; Barnes MN; Lewandowski G; Mannel RS;
    Gynecol Oncol; 2008 Mar; 108(3):493-9. PubMed ID: 18191993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
    Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
    Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.